Biomarkers in Cancer Screening and Early Detection by Sudhir Srivastava (English

Description: Biomarkers in Cancer Screening and Early Detection by Sudhir Srivastava Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. FORMAT Hardcover LANGUAGE English CONDITION Brand New Publisher Description Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment. Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkersProvides immediately actionable information – and hopefully also inspiration – to move discovery and clinical application forwardOffers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers Back Cover Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and clinical use. The primary purpose of this book is to summarize and present best practices in this field to date, and offer actionable information - and hopefully also inspiration - to move discovery and clinical application forward. This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection is organized into three sections: Section I lays the foundation for biomarker discovery, development and validation. Section II presents organ-specific topics relevant to the clinical needs in early detection, the natural history of the disease and associated evidence in support of biomarker research, an overview of the current state-of-the art in biomarker research, current progress toward bringing these biomarkers into clinical use and the future of biomarker-based screening and early detection for the respective organ type. Finally, Section III offers chapters that address the current screening strategies for selected organ types, discuss deficiencies with the present practice and identify clinical needs that may benefit from biomarker-based approaches. This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection: Provides immediately actionable information - and hopefully also inspiration - to move discovery and clinical application forward Considers the cutting edge "bench to bedside and back" breakthroughs which have transformed the diagnosis, prognosis and treatment of cancer Discusses screening guidelines, research strategies, and issues surrounding cancer overdiagnosis Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers The development of cancer is preceded by numerous mutations and changes which transform normal cells into benign tumors, and progressively into malignant and metastatic forms. This enormous complexity makes cancer detection, diagnosis, and treatment challenging and therefore the ability to identify tumors that are destined to progress at an early stage will allow effective treatment interventions and reduce deaths. This new book comprehensively summarises the current state of play and is an ideal resource for clinical and research oncologists interested in the progress of screening and detection of cancer. Flap Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and clinical use. The primary purpose of this book is to summarize and present best practices in this field to date, and offer actionable information - and hopefully also inspiration - to move discovery and clinical application forward. This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection is organized into three sections: Section I lays the foundation for biomarker discovery, development and validation. Section II presents organ-specific topics relevant to the clinical needs in early detection, the natural history of the disease and associated evidence in support of biomarker research, an overview of the current state-of-the art in biomarker research, current progress toward bringing these biomarkers into clinical use and the future of biomarker-based screening and early detection for the respective organ type. Finally, Section III offers chapters that address the current screening strategies for selected organ types, discuss deficiencies with the present practice and identify clinical needs that may benefit from biomarker-based approaches. This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection: Provides immediately actionable information - and hopefully also inspiration - to move discovery and clinical application forward Considers the cutting edge "bench to bedside and back" breakthroughs which have transformed the diagnosis, prognosis and treatment of cancer Discusses screening guidelines, research strategies, and issues surrounding cancer overdiagnosis Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers The development of cancer is preceded by numerous mutations and changes which transform normal cells into benign tumors, and progressively into malignant and metastatic forms. This enormous complexity makes cancer detection, diagnosis, and treatment challenging and therefore the ability to identify tumors that are destined to progress at an early stage will allow effective treatment interventions and reduce deaths. This new book comprehensively summarises the current state of play and is an ideal resource for clinical and research oncologists interested in the progress of screening and detection of cancer. Author Biography Edited by Sudhir Srivastava, Ph.D., MPH Senior Scientific Officer, Chief, Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Translational Oncology Series Series Editors ROBERT C. BAST, MD, Vice President for Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA MAURIE MARKMAN, MD, Senior Vice President for Clinical Affairs, Cancer Treatment Centers of America, Clinical Professor of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA ERNEST HAWK, MD, MPH, Vice President, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Table of Contents List of Contributors, ix Preface, xiii Part I Foundations of Biomarker Research 1 Nuts and Bolts of Biomarker Research, 3Sharmistha Ghosh and Sudhir Srivastava 2 Cancer Genome Methylation: Biology, Biomarker and Therapeutic Opportunities, 16Shashwat Sharad, Taduru Sreenath, Shiv Srivastava, and Albert Dobi 3 MicroRNA Biomarkers for Early Detection of Cancer, 27WendyWang, Matthew R Young, and Sudhir Srivastava 4 Inflammation and Cancer, 37Pamela L Beatty, Sandra Cascio, and Olivera J Finn 5 Exosomes: A Valuable Biomedical Tool in Biomarker Discovery and Development, 50Jocelyn Lee, Sharmistha Ghosh, and Sudhir Srivastava 6 Epithelial-to-Mesenchymal Transition (EMT): Clinical Implications, 64Elisa CWoodhouse and Suresh Mohla Part II State-of-the-Science in Organ-Specific Biomarker Research 7 Breast Cancer, 77Benjamin A Katchman, Christos Patriotis, and Karen S Anderson 8 Ovarian Cancer, 93Christos Patriotis, Archana Simmons, Karen H Lu, Robert C Bast, Jr, and Steven J Skates 9 Esophageal Cancer Biomarkers, 104Yanxin Luo, Kishore Guda, SanfordD Markowitz, Amitabh Chak, Andrew M Kaz, andWilliam M Grady 10 Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract, 118Heath D Skinner, Qiongrong Chen, Elena Elimova, RoopmaWadhwa, Shumei Song, and Jaffer A Ajani 11 Pancreatic Cancer, 130Sam CWang and Peter J Allen 12 Colon Cancer, 141Paul DWagner 13 Prognostic and Predictive Biomarkers for Colorectal Cancer, 151Upender Manne, Balananda-Dhurjati Kumar Putcha, Temesgen Samuel, and Sudhir Srivastava 14 Early Detection of Lung Cancer, 163Mohamed Hassanein, Melinda C Aldrich, Stephen A Deppen, Karl E Krueger, Eric L Grogan, and Pierre P Massion 15 Commonalities in Lung Cancer and COPD, 185MalgorzataWojtowicz and Eva Szabo 16 Prostate Cancer, 197Jacob Kagan, Ian M Thompson, and DanielWChan Part III Biomarkers, Screening and Precision Health: Implications for Public Health 17 Improving the Clinical Validity of Biomarker Research in Cancer Detection, 209David F Ransohoff 18 Cancer Overdiagnosis, Ramifications and Research Strategies, 220Barbara K Dunn and Barnett S Kramer 19 Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis, 231Brian S Sorg, Sarfraz Memon, Kelly Y Kim, Aniruddha Ganguly, Tracy Lively, James Tricoli, Magdalena Thurin, Lokesh Agrawal, Tawnya C McKee, Barbara A Conley, and J Milburn Jessup 20 Statistical Consideration in Predictive and Prognostic Markers, 245Fei Ye and Yu Shyr 21 Clinical Validation of Molecular Biomarkers in Translational Medicine, 256Harry B Burke and William E Grizzle 22 Cancer Biomarker Assays: Performance Standards, 267Anna K Fuzery and Daniel W Chan 23 Bioethics and Cancer Biomarker Research, 277Nathan Nobis, William Grizzle, and Stephen Sodeke 24 Colon Cancer Screening, 283Molly Perencevich, Jennifer Inra, and Sapna Syngal Long Description Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and clinical use. The primary purpose of this book is to summarize and present best practices in this field to date, and offer actionable information and hopefully also inspiration to move discovery and clinical application forward. This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection is organized into three sections: Section I lays the foundation for biomarker discovery, development and validation. Section II presents organ-specific topics relevant to the clinical needs in early detection, the natural history of the disease and associated evidence in support of biomarker research, an overview of the current state-of-the art in biomarker research, current progress toward bringing these biomarkers into clinical use and the future of biomarker-based screening and early detection for the respective organ type. Finally, Section III offers chapters that address the current screening strategies for selected organ types, discuss deficiencies with the present practice and identify clinical needs that may benefit from biomarker-based approaches. This latest volume of the Translational Oncology series, Biomarkers in Cancer Screening and Early Detection: Provides immediately actionable information and hopefully also inspiration to move discovery and clinical application forward Considers the cutting edge "bench to bedside and back" breakthroughs which have transformed the diagnosis, prognosis and treatment of cancer Discusses screening guidelines, research strategies, and issues surrounding cancer overdiagnosis Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers The development of cancer is preceded by numerous mutations and changes which transform normal cells into benign tumors, and progressively into malignant and metastatic forms. This enormous complexity makes cancer detection, diagnosis, and treatment challenging and therefore the ability to identify tumors that are destined to progress at an early stage will allow effective treatment interventions and reduce deaths. This new book comprehensively summarises the current state of play and is an ideal resource for clinical and research oncologists interested in the progress of screening and detection of cancer. Details ISBN1118468805 Author Sudhir Srivastava Short Title BIOMARKERS IN CANCER SCREENING Language English ISBN-10 1118468805 ISBN-13 9781118468807 Media Book Format Hardcover Series Translational Oncology Edition 1st Edited by Sudhir Srivastava DEWEY 616.994075 Year 2017 Series Number 3 Publication Date 2017-08-25 UK Release Date 2017-08-25 NZ Release Date 2017-08-28 Pages 320 Publisher John Wiley and Sons Ltd Imprint Wiley-Blackwell Place of Publication Hoboken Audience Professional & Vocational US Release Date 2017-08-25 AU Release Date 2017-08-06 Country of Publication United Kingdom We've got this At The Nile, if you're looking for it, we've got it. With fast shipping, low prices, friendly service and well over a million items - you're bound to find what you want, at a price you'll love! TheNile_Item_ID:99114885;

Price: 193.49 AUD

Location: Melbourne

End Time: 2024-12-22T09:04:53.000Z

Shipping Cost: 15.06 AUD